DALLAS – June 23, 2021 – UT Southwestern will lead a multicenter investigation into why children and young adults experience decreased physical activity and shortness of breath after experiencing blood clots, thanks to a four-year $2.97 million grant from the National Institutes of Health (NIH).
Irvine, Calif., June 21, 2021 — A large-scale meta-analysis led by University of California, Irvine researchers provides the strongest evidence yet of which blood pressure medications help slow memory loss in older adults: those that can travel out of blood vessels and directly into the brain. The findings, published in the American Heart Association journal Hypertension, will be of interest to the 91 million Americans whose blood pressure is high enough to warrant medication, as well as the doctors who treat them.
Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.
A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma — the pale yellow liquid in blood that is rich in antibodies — from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection.
In a new paper published in the journal Circulation, researchers built a model to examine the potential impact of implementing similar blood pressure control programs at barbershops nationwide. Modeled off a 2018 randomized trial called the Los Angeles Barbershop Blood Pressure Study (LABBS), the team found that such programs could reach one in three Black men with uncontrolled blood pressure nationally.
The treatment’s effectiveness was described in a report describing three Canadian patients who received the AstraZeneca vaccine, and who subsequently developed VITT. Two suffered clotting in their legs and the third had clots blocking arteries and veins inside their brain.
New research by the Georgia Institute of Technology and Emory University published in the journal Biomaterials sheds new light on the mechanics and physics of blood clotting through modeling the dynamics at play during a still poorly understood phase of blood clotting called clot contraction. Understanding the physics of this clot contraction could potentially lead to new ways to treat bleeding problems and clotting problems.
Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin. Using a viral vector engineered to reactivate fetal hemoglobin production, suppress mutant hemoglobin, and supply functional adult hemoglobin, the researchers developed an approach that could produce more hemoglobin through a single vector. The results were published in Haematologica.
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company's Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The study will evaluate the safety and efficacy of infusing multiple dose levels of Thrombosomes versus standard liquid stored platelets.
Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine.
Along with a first-place winner, there are two honorable mentions in the Vasculitis Foundation’s (VFs) 2021 Recognizing Excellence in Diagnostics (V-RED) award program.
A rare syndrome has been observed in people following vaccination against Covid-19.
National STOP THE BLEED® Day provides a renewed opportunity to highlight why it’s important that everyone learn how to control serious bleeding.
Researchers at Rutgers Robert Wood Johnson Medical School are reporting the first instance of COVID-19 triggering a rare recurrence of potentially serious blood clots in people’s arms.
RNA-based drugs may change the standard of care for many diseases, making personalized medicine a reality. So far these cost-effective, easy-to-manufacture drugs haven’t been very useful in treating brain tumors and other brain disease. But a team of researchers at Georgia Tech and Emory University has shown that a combination of ultrasound and RNA-loaded nanoparticles can temporarily open the protective blood-brain barrier, allowing the delivery of potent medicine to brain tumors.
A University of Kentucky College of Medicine professor has been awarded a $1.9 million NIH grant for his research on the body’s immune response to sepsis, which could potentially help to improve therapies for the common disease.
Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have found a major molecular “switch” that controls how cells turn their genes on and off. This process ensures the cell correctly and adequately performs its assigned tasks in the body. The research team’s discovery will likely improve the understanding of how normal stem cells function, and could possibly lead to insights into disease.
New resource from NCCN helps cancer patients and caregivers recognize and understand blood cell production deficiencies, to better participate in their care planning; available for free at NCCN.org/patientguidelines.
People with certain blood types are more likely to have blood clots or bleeding conditions, kidney stones, or pregnancy-induced hypertension, suggests a study published today in eLife.
A combination of inexpensive oral medications may be able to treat fatigue-inducing anemias caused by chronic diseases and inflammation, a new discovery from the University of Virginia School of Medicine suggests.
Tourniquet use has been consistently increasing in Los Angeles County since 2015 and is significantly associated with improved patient survival.
Penn Medicine researchers discovered that less is more when it comes to the length of what is known as the single-chain variable fragment in CAR T cells.
A real-life forensic puzzle inspired University of Illinois at Chicago and Iowa State University researchers to explore the physics involved, and in Physics of Fluids, they present theoretical results revealing an interaction of the incoming vortex ring of propellant muzzle gases with backward blood spatter. A detailed analytical theory of such turbulent self-similar vortex rings was given by this group in earlier work and is linked mathematically to the theory of quantum oscillators.
Researchers from Rutgers Cancer Institute of New Jersey, recently discovered that a mitochondrial uncoupling drug is toxic against leukemic cells, revealing a potential therapeutic strategy against T-ALL.
The first large-scale, multi-hospital evaluation of an “all or none” federal policy intended to improve results in sepsis patients finds that the guidelines are a wash – on average they neither helped nor hurt outcomes despite significant investments in their implementation.
In a study by Yale Cancer Center, researchers report on the discovery of a common mechanism that promotes both autoimmune diseases and blood cancers, including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL).
Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer.
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies, potentially in combination with immune tolerance therapies, to tame the immune response in some patients with severe hemophilia A.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. The foundational study, published in the journal Blood, is a first step toward finding effective treatments for the hard-to-treat blood cancer.
Only a few treatment options exist for sickle cell patients. Today, researchers report discovery of a small molecule that could treat sickle cell disease by boosting levels of fetal hemoglobin, a healthy form that adults normally do not make. They will present their results at ACS Spring 2021.
Surprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases.
The risk of childhood leukemia among kids with Down syndrome is higher than predicted, according to a new study led by UC Davis and UC San Francisco researchers. Early diagnosis remains critical.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.
Worldwide, 1 in 4 people will suffer from a depressive episode in their lifetime. While current diagnosis and treatment approaches are largely trial and error, a breakthrough study by Indiana University School of Medicine researchers sheds new light on the biological basis of mood disorders and offers a promising blood test aimed at a precision-medicine approach to treatment.
During GVN’s 9th International Meeting in Melbourne, Australia on September 25-27, 2017 in partnership with the Peter Doherty Institute and the Institut Pasteur, researchers held impressive sessions on one of the most potent human carcinogens, human T cell leukemia virus-1 (HTLV-1).
UC San Diego researchers discovered that patient survival from sepsis is associated with higher platelet counts, and identified two currently available drugs that protect these blood cells and improve survival in mice with sepsis.
Blood from critically ill COVID-19 patients contains antibodies that can contribute to clotting. These antibodies form immune complexes that activate platelets, the cells that lead to blood clot formation. Some blood-thinner medications can block these immune complexes and potentially reduce clots.
Cecelia Calhoun, MD, MSPH, MBA, has been appointed Assistant Professor of Medicine (Hematology) and Assistant Professor of Pediatrics (Hematology/Oncology) at Yale Cancer Center and Smilow Cancer Hospital
Expert from Rutgers Cancer Institute of New Jersey shares information on symptoms, treatment and more to highlight multiple myeloma awareness month.
Only 3% of patients at high risk for primary aldosteronism (PA), a common disorder that causes high blood pressure and can lead to heart and kidney complications, are screened for the condition, according to a study that will be presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Electric stimulation may be able to help blood vessels carry white blood cells and oxygen to wounds, speeding healing, a new study suggests.
A new study from Washington University School of Medicine in St. Louis shows that whole genome sequencing is at least as accurate and often better than conventional genetic tests that help determine the treatment for a patient’s blood cancer. Genome sequencing technology continuously is decreasing in cost and recently reached a level similar to that of conventional testing.
A new study from the University of California, Irvine shows that compounds in both green and black tea relax blood vessels by activating ion channel proteins in the blood vessel wall. The discovery helps explain the antihypertensive properties of tea and could lead to the design of new blood pressure-lowering medications.
In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right